Design and Molecular Docking Study of Antimycin A3 Analogues as Inhibitors of Anti-Apoptotic Bcl-2 of Breast Cancer

Ade Arsianti, Fadilah, Kusmardi, Hiroki Tanimoto, Tsumoru Morimoto, Kiyomi Kakiuchi
2014 Open Journal of Medicinal Chemistry  
In this paper, we report the design and moleculardocking study of analogues of antimycin A 3 as inhibitors of anti-apoptotic Bcl-2 of breast cancer. Twenty designed compounds and the original antimycin A 3 were docked based on their interaction with breast tumor receptor binding target Bcl-2. The docking resulted in the five top-ranked compounds, namely, compounds 11, 14, 15, 16, and 20, which have a lower ∆G binding energy, better affinity and stronger hydrogen bonding interactions to the
more » ... actions to the active site of Bcl-2 than antimycin A 3 . Among those five top-ranked compounds, analogue compounds 11 and 14, which have an 18-membered tetralactone core and 18-membered tetraol core, respectively, exhibited the strongest hydrogen bond interaction, formed high stability conformation, and demonstrated the greatest inhibitory activity on the catalytic site of Bcl-2.
doi:10.4236/ojmc.2014.43006 fatcat:uah6ai2uujgyhm2elgo66mnyju